Nesfatin-1 and other hormone alterations in polycystic ovary syndrome
| dc.contributor.author | Deniz, Rulin | |
| dc.contributor.author | Gurates, Bilgin | |
| dc.contributor.author | Aydin, Suleyman | |
| dc.contributor.author | Celik, Husnu | |
| dc.contributor.author | Sahin, Ibrahim | |
| dc.contributor.author | Baykus, Yakup | |
| dc.contributor.author | Gungor, Sami | |
| dc.date.accessioned | 2026-08-12T17:31:53Z | |
| dc.date.issued | 2012 | |
| dc.department | Fırat Üniversitesi | |
| dc.description.abstract | Polycystic ovary syndrome (PCOS) is commonly characterised by obesity, insulin resistance (IR), hyperandrogenemia and hirsutism. Nesfatin-1 a recently discovered hormone, acts upon energy balance, glucose metabolism, obesity and probably gonadal functions. This study was to evaluate the circulating levels of nesfatin-1 in patients with PCOS (n = 30) and in age and body mass index (BMI)-matched controls (n = 30). PCOS patients had significantly lower levels of nesfatin-1 (0.88 +/- A 0.36 ng/mL) than healthy controls (2.22 +/- A 1.14 ng/mL). PCOS patients also had higher gonadotropin and androgen plasma concentrations, Ferriman-Gallwey scores, blood glucose levels and a homeostasis model of assessment-IR index (HOMA-IR) index than in healthy women. Correlation tests in PCOS subjects detected a negative correlation between nesfatin-1 levels and BMI, fasting blood glucose, insulin levels and a HOMA-IR index. Lower nesfatin-1 concentration may plays a very important role in the development of PCOS. | |
| dc.description.sponsorship | FUBAP [1889] | |
| dc.description.sponsorship | The authors like to extend their thanks to FUBAP for their financial support (project number 1889). And also their heartfelt thanks and never ending admiration to Harry Miller for his editing this manuscript. | |
| dc.identifier.doi | 10.1007/s12020-012-9638-7 | |
| dc.identifier.endpage | 699 | |
| dc.identifier.issn | 1355-008X | |
| dc.identifier.issn | 1559-0100 | |
| dc.identifier.issue | 3 | |
| dc.identifier.orcid | 0000-0002-3006-4035 | |
| dc.identifier.pmid | 22367584 | |
| dc.identifier.scopus | 2-s2.0-84878227004 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | 694 | |
| dc.identifier.uri | https://doi.org/10.1007/s12020-012-9638-7 | |
| dc.identifier.uri | https://hdl.handle.net/11508/56430 | |
| dc.identifier.volume | 42 | |
| dc.identifier.wos | WOS:000312073500034 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Springer | |
| dc.relation.ispartof | Endocrine | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WoS_20260511 | |
| dc.subject | PCOS | |
| dc.subject | Nesfatin-1 | |
| dc.subject | Ferriman-Gallwey scores | |
| dc.title | Nesfatin-1 and other hormone alterations in polycystic ovary syndrome | |
| dc.type | Article |







